CD34 and acute myeloid leukemia: The WNT/β-catenin inhibitor BC2059 demonstrates significant killing efficiency against the CD34+CD38−Lin− stem cell/progenitor cell population in FLT3/ITD+ AML.11 Retinoic acid combined with FLT3-TKIs can effectively remove FLT3/ITD+ LSCs and prolong survival in FLT3/ITD+ AML xenograft models.12 However, the effects of Notch signaling in FLT3/ITD+ AML remain to be elucidated.